Seattle-based Cardeas Pharma, a startup led by prominent biotech entrepreneur A. Bruce Montgomery, has raised its first $1 million, according to a regulatory filing. The company only lists two executives and members of its board—Montgomery and Melissa Yaeger, an experienced drug developer who previously worked with Montgomery at Seattle-based Corus Pharma and Gilead Sciences. Montgomery, who left his role as a senior vice president at Gilead in August, hasn’t yet talked publicly about what Cardeas is setting out to do.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
